Max India board to meet on May 28 to consider FY26 results

Max India Limited has informed the stock exchanges that its board meeting is scheduled to be held on Thursday, May 28, 2026. The meeting has been convened to consider the audited financial results of the company for the financial year ended on March 31, 2026. The board will review both standalone and consolidated financial statements during the session.

Agenda for the Meeting

The primary agenda for the upcoming board meeting is the consideration and approval of the audited financial results for the full financial year. This follows the company's earlier announcement dated March 27, 2026, regarding the meeting schedule.

Trading Window Closure

Pursuant to the company's Policy on Prevention of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in shares of the company will remain closed. This restriction applies to all designated persons of the company, including their immediate relatives.

The trading window shall stay closed until the completion of 48 hours from the announcement of the audited financial results to the stock exchanges. Consequently, the window is expected to reopen on Saturday, May 30, 2026.

Key Dates

Event	Date
Board Meeting	May 28, 2026
Financial Year End	March 31, 2026
Trading Window Reopens	May 30, 2026

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.92%	-5.72%	+0.11%	-20.05%	-17.04%	+136.45%

Max India Limited has announced the appointment of Ms. Mrinalini Mirchandani as Additional Director in the capacity of Independent Director. The Board of Directors approved this appointment on April 9, 2026 via circular resolution, following the recommendation of the Nomination and Remuneration Committee.

Appointment Details

The appointment encompasses a five-year term commencing on April 15, 2026 and concluding on April 14, 2031. The decision is subject to approval from shareholders and has been disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Parameter:	Details
Director Name:	Ms. Mrinalini Mirchandani
DIN:	11619010
Position:	Additional Director (Independent Director)
Term Duration:	5 years
Commencement Date:	April 15, 2026
End Date:	April 14, 2031
Approval Status:	Subject to shareholder approval

Professional Background

Ms. Mirchandani brings distinguished experience from her tenure at McKinsey & Company, where she served as Senior Partner. She holds the distinction of being the first and only woman elected to the Senior Partner position in McKinsey's 34-year history in India.

At McKinsey, she led the Private Equity Practice in India and served as a member of the global healthcare leadership team. Her responsibilities also included overseeing the Organization & Talent practice in India. Prior to McKinsey, she worked at Merrill Lynch, leading their Healthcare & Consumer Investment Banking Team in India, and headed the Healthcare recruiting practice for Egon Zehnder in India.

Educational Qualifications and Recognition

Ms. Mirchandani holds an MBA from IIM Calcutta and a B.Com from Mumbai University. Her professional achievements were recognized in 2018 when she was featured in the Economic Times list of India's 40 under Forty Young Business Leaders.

Regulatory Compliance

The company has confirmed that Ms. Mirchandani is not related to any other Director of the Company and is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other authority. The appointment disclosure complies with all requirements under SEBI listing regulations and relevant circulars.

Over the past two decades, Ms. Mirchandani has collaborated with leading Indian and global institutions on various strategic initiatives including growth strategy, mergers and acquisitions, capital raising, talent management, and delivering transformational change at scale.